The underlying index of the Stock Connect Innovative Drug ETF E Fund (159316) rose by over 1%, attracting over 1.6 billion in recent months.

As of 9:50, the Hang Seng Stock Connect Innovative Drug Index (HSSCID) rose by 1.19%. Among the top ten weighted stocks, Innovent Biologics rose 2.17%, BeiGene rose 2.23%, CSPC Pharmaceutical Group rose 0.36%, Akeso rose 7.51%, China National Pharmaceutical Group rose 2.35%, Hansoh Pharmaceutical rose 1.84%, Simcere Pharmaceutical rose 4.37%, Kelun-Biotech rose 2.83%, Zai Lab rose 2.45%, and Conage rose 0.34%.

The Hang Seng Stock Connect Innovative Drug ETF E Fund (159316) continues to attract capital inflows, with a net capital inflow of 24.9706 million yuan in the previous trading day. As of the previous trading day, the fund had a cumulative net inflow of 356 million yuan over the past week, 163.8 million yuan over the past month, 226.3 million yuan over the past three months, 279.1 million yuan over the past six months, and 688.9 million yuan over the past year. The fund's average daily turnover for the past month was 1.504 billion yuan, ranking first among its peers, with active on-exchange trading and strong liquidity.

In terms of news, the National Medical Products Administration announced that a new targeted innovative drug, developed and declared simultaneously globally, has been approved for market launch in China today, marking a historic breakthrough for an original targeted innovative drug developed through global multi-center clinical trials to be reported and launched first in China. The NMPA recently approved the listing of "Selective Orexin 2 Receptor Agonist," a new targeted, new mechanism innovative drug used to treat type 1 narcolepsy in adolescents aged 16 and above and adults.

It is understood that this innovative drug is a rare disease treatment medication, with marketing applications submitted simultaneously in multiple countries and regions worldwide. It has been recognized as a breakthrough therapy product in China and included in the priority review and approval procedure, gaining access to a "double acceleration channel." In the US, it has been granted breakthrough therapy designation and included in the fast track program. In Japan, it has received pioneer and orphan drug qualifications, entering the fast review and approval process. In the EU, it has been granted orphan drug status.

Guojin Securities released a research report stating that from an industry perspective, China's innovative drug pipeline reserves are globally leading, with significant advantages in review, clinical trials, and costs, deeply embedded in the global industrial chain. On the performance side, ample backend pipeline reserves, coupled with bidirectional empowerment from medical insurance and essential drug policies, have ushered the industry into a golden window for performance realization. From the dual dimensions of pipeline supply and policy review, China's innovative drug industry has officially entered a period of concentrated commercialization and performance realization.

The management fee rate for the Hang Seng Stock Connect Innovative Drug ETF E Fund (159316) is 0.15%, the custody fee rate is 0.05%, and the comprehensive fee rate is 0.2%. The lower fee structure effectively helps investors reduce cost expenditures.

The Hang Seng Stock Connect Innovative Drug ETF E Fund (159316) is currently the only ETF product tracking the Hang Seng Innovative Drug Index in the market, possessing high elasticity and scarcity, helping investors better seize investment opportunities in Hong Kong's innovative drug sector this round.

Related products:

Hang Seng Stock Connect Innovative Drug ETF E Fund (159316)

E Fund Hang Seng Stock Connect Innovative Drug Feeder Fund Class A (024328)

E Fund Hang Seng Stock Connect Innovative Drug Feeder Fund Class C (024329)

Innovative Drug ETF E Fund (516080), Off-exchange feeder (Class A: 019666; Class C: 019667)

Hang Seng Stock Connect Healthcare ETF (513200), Off-exchange feeder (Class A: 018557; Class C: 018558)

Healthcare ETF (512010), Off-exchange feeder (Class A: 001344; Class C: 007883)

Medical 50 ETF (159847), Off-exchange feeder (Class A: 017937; Class C: 017938)

Biotechnology ETF (159837)